A citation-based method for searching scientific literature

Zsofia Sztupinszki, Miklos Diossy, Judit Borcsok, Aurel Prosz, Nanna Cornelius, Maj K Kjeldsen, Mansoor R Mirza, Zoltan Szallasi. Clin Cancer Res 2021
Times Cited: 5







List of co-cited articles
29 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Andrew Tutt, Holly Tovey, Maggie Chon U Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazinska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett-Lee,[...]. Nat Med 2018
412
80

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
444
80

Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Kirsten M Timms, Victor Abkevich, Elisha Hughes, Chris Neff, Julia Reid, Brian Morris, Saritha Kalva, Jennifer Potter, Thanh V Tran, Jian Chen,[...]. Breast Cancer Res 2014
207
60

Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
Euan A Stronach, James Paul, Kirsten M Timms, Elisha Hughes, Krystal Brown, Christopher Neff, Michael Perry, Alexander Gutin, Mona El-Bahrawy, Jennifer H Steel,[...]. Mol Cancer Res 2018
52
60

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Helen Davies, Dominik Glodzik, Sandro Morganella, Lucy R Yates, Johan Staaf, Xueqing Zou, Manasa Ramakrishna, Sancha Martin, Sandrine Boyault, Anieta M Sieuwerts,[...]. Nat Med 2017
445
60

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
R E Miller, A Leary, C L Scott, V Serra, C J Lord, D Bowtell, D K Chang, D W Garsed, J Jonkers, J A Ledermann,[...]. Ann Oncol 2020
86
60

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Isabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martín, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää,[...]. N Engl J Med 2019
536
60

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
566
60

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
60


Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia,[...]. Lancet 2017
826
60

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer,[...]. N Engl J Med 2019
645
60

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, William M Sikov, Hope S Rugo, Mark D McKee, Jens Huober, Mehra Golshan, Gunter von Minckwitz, David Maag,[...]. Lancet Oncol 2018
328
40

Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Yuan, Jin Sun Lee, Susan E Yost, Sierra Min Li, Paul H Frankel, Christopher Ruel, Daniel Schmolze, Kim Robinson, Aileen Tang, Norma Martinez,[...]. Oncologist 2021
14
40

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Nicolai J Birkbak, Zhigang C Wang, Ji-Young Kim, Aron C Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J Dirk Iglehart,[...]. Cancer Discov 2012
296
40

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Elizabeth M Swisher, Kevin K Lin, Amit M Oza, Clare L Scott, Heidi Giordano, James Sun, Gottfried E Konecny, Robert L Coleman, Anna V Tinker, David M O'Malley,[...]. Lancet Oncol 2017
682
40

The repertoire of mutational signatures in human cancer.
Ludmil B Alexandrov, Jaegil Kim, Nicholas J Haradhvala, Mi Ni Huang, Alvin Wei Tian Ng, Yang Wu, Arnoud Boot, Kyle R Covington, Dmitry A Gordenin, Erik N Bergstrom,[...]. Nature 2020
901
40

Genome-wide transcriptome profiling of homologous recombination DNA repair.
Guang Peng, Curtis Chun-Jen Lin, Wei Mo, Hui Dai, Yun-Yong Park, Soo Mi Kim, Yang Peng, Qianxing Mo, Stefan Siwko, Ruozhen Hu,[...]. Nat Commun 2014
141
40

Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes.
Nadeem Riaz, Pedro Blecua, Raymond S Lim, Ronglai Shen, Daniel S Higginson, Nils Weinhold, Larry Norton, Britta Weigelt, Simon N Powell, Jorge S Reis-Filho. Nat Commun 2017
143
40

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Nora Sahnane, Ileana Carnevali, Giorgio Formenti, Jvan Casarin, Sofia Facchi, Raffaella Bombelli, Eleonora Di Lauro, Domenico Memoli, Annamaria Salvati, Francesca Rizzo,[...]. Int J Mol Sci 2020
8
40

Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
Panagiotis A Konstantinopoulos, Dimitrios Spentzos, Beth Y Karlan, Toshiyasu Taniguchi, Elena Fountzilas, Nancy Francoeur, Douglas A Levine, Stephen A Cannistra. J Clin Oncol 2010
345
40

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Hisamitsu Takaya, Hidekatsu Nakai, Shiro Takamatsu, Masaki Mandai, Noriomi Matsumura. Sci Rep 2020
63
40

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Kara N Maxwell, Bradley Wubbenhorst, Brandon M Wenz, Daniel De Sloover, John Pluta, Lyndsey Emery, Amanda Barrett, Adam A Kraya, Ioannis N Anastopoulos, Shun Yu,[...]. Nat Commun 2017
136
40

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
Panagiotis A Konstantinopoulos, Raphael Ceccaldi, Geoffrey I Shapiro, Alan D D'Andrea. Cancer Discov 2015
422
40

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen,[...]. Br J Cancer 2012
385
40

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Tatiana Popova, Elodie Manié, Guillaume Rieunier, Virginie Caux-Moncoutier, Carole Tirapo, Thierry Dubois, Olivier Delattre, Brigitte Sigal-Zafrani, Marc Bollet, Michel Longy,[...]. Cancer Res 2012
345
40

Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Amir A Jazaeri, Cindy J Yee, Christos Sotiriou, Kelly R Brantley, Jeff Boyd, Edison T Liu. J Natl Cancer Inst 2002
198
40

Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.
Theo A Knijnenburg, Linghua Wang, Michael T Zimmermann, Nyasha Chambwe, Galen F Gao, Andrew D Cherniack, Huihui Fan, Hui Shen, Gregory P Way, Casey S Greene,[...]. Cell Rep 2018
421
40

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Serena Nik-Zainal, Helen Davies, Johan Staaf, Manasa Ramakrishna, Dominik Glodzik, Xueqing Zou, Inigo Martincorena, Ludmil B Alexandrov, Sancha Martin, David C Wedge,[...]. Nature 2016
40


Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).
Christel Fontaine, Vincent Renard, Heidi Van den Bulk, Peter Vuylsteke, Philip Glorieux, Catherine Dopchie, Lore Decoster, Leen Vanacker, Evandro de Azambuja, Jacques De Greve,[...]. Breast Cancer Res Treat 2019
4
25

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
20

Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
Jenny Furlanetto, Volker Möbus, Andreas Schneeweiss, Kerstin Rhiem, Hans Tesch, Jens-Uwe Blohmer, Kristina Lübbe, Michael Untch, Christoph Salat, Jens Huober,[...]. Eur J Cancer 2021
2
50

Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
Rachel Greenup, Adam Buchanan, Wendy Lorizio, Keelia Rhoads, Salina Chan, Tracey Leedom, Robin King, Jane McLennan, Beth Crawford, P Kelly Marcom,[...]. Ann Surg Oncol 2013
131
20

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
S Loibl, K E Weber, K M Timms, E P Elkin, E Hahnen, P A Fasching, B Lederer, C Denkert, A Schneeweiss, S Braun,[...]. Ann Oncol 2018
122
20

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Daniel P Silver, Andrea L Richardson, Aron C Eklund, Zhigang C Wang, Zoltan Szallasi, Qiyuan Li, Nicolai Juul, Chee-Onn Leong, Diana Calogrias, Ayodele Buraimoh,[...]. J Clin Oncol 2010
687
20

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
E L Mayer, V Abramson, R Jankowitz, C Falkson, P K Marcom, T Traina, L Carey, M Rimawi, J Specht, K Miller,[...]. Ann Oncol 2020
20
20

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
Eric Hahnen, Bianca Lederer, Jan Hauke, Sibylle Loibl, Sandra Kröber, Andreas Schneeweiss, Carsten Denkert, Peter A Fasching, Jens U Blohmer, Christian Jackisch,[...]. JAMA Oncol 2017
196
20

Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
Tal Sella, Einav Nili Gal Yam, Keren Levanon, Tal Shapira Rotenberg, Moran Gadot, Iryna Kuchuk, Rinat Bernstein Molho, Amit Itai, Tami Mekel Modiano, Raya Gold,[...]. Breast 2018
9
20

The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.
Thomas P Slavin, Kara N Maxwell, Jenna Lilyquist, Joseph Vijai, Susan L Neuhausen, Steven N Hart, Vignesh Ravichandran, Tinu Thomas, Ann Maria, Danylo Villano,[...]. NPJ Breast Cancer 2017
81
20

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).
Nadine Tung, Banu Arun, Michele R Hacker, Erin Hofstatter, Deborah L Toppmeyer, Steven J Isakoff, Virginia Borges, Robert D Legare, Claudine Isaacs, Antonio C Wolff,[...]. J Clin Oncol 2020
52
20

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
David Moher, Larissa Shamseer, Mike Clarke, Davina Ghersi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart. Syst Rev 2015
20

Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
Milos Holanek, Iveta Selingerova, Ondrej Bilek, Tomas Kazda, Pavel Fabian, Lenka Foretova, Maria Zvarikova, Radka Obermannova, Ivana Kolouskova, Oldrich Coufal,[...]. Cancers (Basel) 2021
2
50

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
Anne-Renee Hartman, Rajesh R Kaldate, Lisa M Sailer, Lisa Painter, Charles E Grier, Robbin R Endsley, Marlena Griffin, Stephanie A Hamilton, Cynthia A Frye, Mark A Silberman,[...]. Cancer 2012
128
20


Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis.
Ramy R Saleh, Michelle B Nadler, Alexandra Desnoyers, Nicholas Meti, Rouhi Fazelzad, Eitan Amir. Cancer Treat Rev 2021
3
33

β-hCG-induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
Satheesh Kumar Sengodan, Sreelatha K Hemalatha, Revathy Nadhan, Thara Somanathan, Arun Peter Mathew, Arkadiusz Chil, Janusz Kopczynski, Rakesh Sathish Nair, Jerald Mahesh Kumar, Priya Srinivas. Carcinogenesis 2019
4
25

Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer.
Juan Zhang, Jie Sun, Jiuan Chen, Lu Yao, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin,[...]. Breast Cancer Res Treat 2016
41
20

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Christoph Engel, Kerstin Rhiem, Eric Hahnen, Sibylle Loibl, Karsten E Weber, Sabine Seiler, Silke Zachariae, Jan Hauke, Barbara Wappenschmidt, Anke Waha,[...]. BMC Cancer 2018
35
20

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance.
Desh Deepak Singh, Amna Parveen, Dharmendra Kumar Yadav. Biomedicines 2021
4
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.